A second major drugmaker just committed to limiting price increases
Thomson Reuters
As a result, the companies that make insulin have been under fire from the public and politicians including US Senator Bernie Sanders.
Now, one of those insulin-makers, Danish pharmaceutical company Novo Nordisk, says it will limit all future drug list price increases from the company to single digit percentages. Novo Nordisk made the announcement on its Website on Nov. 30, but only drew attention to it on Monday.
Novo Nordisk also pledged to keep out of pocket costs low to consumers through patient assistance programs and cheaper forms of insulin, as well as help change up the complicated drug pricing system.
"While we can debate who pays what in different scenarios, it doesn't change the fact that many patients simply can't afford the medicine they need," Novo Nordisk president Jacob Riis wrote on the Website.
Riis also pointed to the difference between the list price the company sets and the net price that drugmakers get after rebates and other interactions with middle men in the supply chain.
According to data from ZS Associates a sales and marketing firm that works in the healthcare industry, Novo Nordisk's rebate rates were 47% in 2014, and 55% in 2015. Across the industry, ZS data shows that rebates paid out to PBMs and insurers have gone up from about $40 billion four years ago to $100-$130 billion by 2016. So while list prices continue to go up, net prices to the drugmakers have stayed mostly flat.
Here's an example of how much the list prices prices have increased for Novo's Novolog over the past 20 years. Since 2006, the list price of Novolog has increased 280%.
Andy Kiersz/Business Insider
Novo Nordisk is now the second company in recent months to commit to single-digit yearly price increases.
In September, Allergan also pledged to put limits on the size and frequency of drug price hikes in a social contract, limiting it to only yearly single-digit percent increases, and it won't happen on drugs that are about to lose patent protection.
Allergan CEO Brent Saunders praised Novo Nordisk's move on Monday.
Pleased to see $NVO taking responsible self regulating pricing actions for patients. Well done! #socialcontract https://t.co/OjYK2omHUG
- Brent Saunders (@brentlsaunders) December 5, 2016
- US buys 81 Soviet-era combat aircraft from Russia's ally costing on average less than $20,000 each, report says
- 2 states where home prices are falling because there are too many houses and not enough buyers
- A couple accidentally shipped their cat in an Amazon return package. It arrived safely 6 days later, hundreds of miles away.
- Upcoming smartphones launching in India in May 2024
- Markets rebound in early trade amid global rally, buying in ICICI Bank and Reliance
- Women in Leadership
- Rupee declines 5 paise to 83.43 against US dollar in early trade
- Election Commission issues notification for sixth phase of Lok Sabha polls
- JNK India IPO allotment date
- JioCinema New Plans
- Realme Narzo 70 Launched
- Apple Let Loose event
- Elon Musk Apology
- RIL cash flows
- Charlie Munger
- Feedbank IPO allotment
- Tata IPO allotment
- Most generous retirement plans
- Broadcom lays off
- Cibil Score vs Cibil Report
- Birla and Bajaj in top Richest
- Nestle Sept 2023 report
- India Equity Market